Med device maker Acclarent’s IPO flatlines — but could be revived
Acclarent, maker of medical devices to treat ear, nose and throat conditions, has become the latest biotech firm to withdraw its IPO due to poor market conditions. It originally filed in June, hoping to bring in $86.3 million to expand marketing and sales activities.
The Menlo Park, Calif. company’s chief financial officer, George Harter, told VentureWire that it will be keeping its eye on the situation, but said he didn’t expect the IPO market to thaw… Continue Reading
Acclarent raies $35M more for sinus treatment
Acclarent, a maker of a device for sinus treatments, has raised $35 million in a third round of funding, VentureWire reports (sub required):
Acclarent, based in Menlo Park, Calif., was founded in June 2004 to develop a balloon sinuplasty device as a less invasive way to treat chronic sinusitis. The device is inserted through the nose via a guidewire into the targeted sinus. The balloon is then inflated, enlarging the sinus openings, allowing for normal drainage…. Continue Reading